ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 337,08
0,22%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Milestone Pharmaceuticals Inc (MIST)

  7. Milestone Pharmaceuticals Inc (MIST) Actualités

MIST

Milestone Pharmaceuticals (MIST)

Milestone Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MIST
DateHeureSourceTitreSymboleSociété
29/05/202413h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
22/05/202414h00GlobeNewswire Inc.Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT AwarenessNASDAQ:MISTMilestone Pharmaceuticals Inc
13/05/202412h59Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MISTMilestone Pharmaceuticals Inc
01/03/202422h52Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MISTMilestone Pharmaceuticals Inc
29/02/202413h00GlobeNewswire Inc.Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded WarrantsNASDAQ:MISTMilestone Pharmaceuticals Inc
28/02/202422h37GlobeNewswire Inc.Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded WarrantsNASDAQ:MISTMilestone Pharmaceuticals Inc
15/02/202402h56Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MISTMilestone Pharmaceuticals Inc
26/12/202314h54Dow Jones NewsMilestone Pharmaceuticals Shares Sink 24% After Receiving Rejection from FDANASDAQ:MISTMilestone Pharmaceuticals Inc
26/12/202313h57Dow Jones NewsMilestone Pharmaceuticals' Etripamil Nasal Spray Application Gets FDA's Refusal to File LetterNASDAQ:MISTMilestone Pharmaceuticals Inc
21/11/202313h00PR Newswire (Canada)Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:MISTMilestone Pharmaceuticals Inc
13/11/202312h57PR Newswire (Canada)Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate UpdatesNASDAQ:MISTMilestone Pharmaceuticals Inc
11/11/202316h00PR Newswire (US)Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023NASDAQ:MISTMilestone Pharmaceuticals Inc
09/11/202322h43Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:MISTMilestone Pharmaceuticals Inc
07/11/202313h00PR Newswire (US)Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVRNASDAQ:MISTMilestone Pharmaceuticals Inc
24/10/202313h00PR Newswire (US)Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for EtripamilNASDAQ:MISTMilestone Pharmaceuticals Inc
06/10/202313h00PR Newswire (US)Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MISTMilestone Pharmaceuticals Inc
27/09/202313h00PR Newswire (US)Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023NASDAQ:MISTMilestone Pharmaceuticals Inc
05/09/202313h00PR Newswire (US)Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:MISTMilestone Pharmaceuticals Inc
10/08/202313h35PR Newswire (Canada)Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate UpdateNASDAQ:MISTMilestone Pharmaceuticals Inc
20/06/202313h00PR Newswire (US)Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The LancetNASDAQ:MISTMilestone Pharmaceuticals Inc
09/06/202322h23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:MISTMilestone Pharmaceuticals Inc
01/06/202313h00PR Newswire (Canada)Milestone Pharmaceuticals to Present at the Jefferies Healthcare ConferenceNASDAQ:MISTMilestone Pharmaceuticals Inc
31/05/202312h02Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:MISTMilestone Pharmaceuticals Inc
30/05/202312h07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:MISTMilestone Pharmaceuticals Inc
22/05/202313h00PR Newswire (Canada)Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular RateNASDAQ:MISTMilestone Pharmaceuticals Inc
15/05/202323h22Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:MISTMilestone Pharmaceuticals Inc
11/05/202313h25Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:MISTMilestone Pharmaceuticals Inc
11/05/202313h16PR Newswire (US)Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate UpdateNASDAQ:MISTMilestone Pharmaceuticals Inc
08/05/202313h00PR Newswire (Canada)Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular RateNASDAQ:MISTMilestone Pharmaceuticals Inc
28/04/202323h22Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:MISTMilestone Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MIST

Dernières Valeurs Consultées

NYSE
DIS
Walt Disney
EU
RNO
Renault
EU
GLE
Societe Generale
EU
AI
Air Liquide
EU
PX1
CAC 40
EU
AF
Air FranceKLM
NASDAQ
AMZN
Amazon.com
FTSE
UKX
FTSE 100
SPI
SP500
S&P 500
EU
VK
Vallourec
EU
BNP
BNP Paribas
EU
MC
Lvmh Moet Hennessy Louis...
COIN
BTCUSD
Bitcoin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés